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Introduction
Cancer patients suffer frequently from poor sleep quality, 
which is often associated with worries, coping with illness, 
pain, and treatment side effects.1-4 Among the various can-
cer types, breast cancer and lung cancer seem to lead most 
often to sleep disturbance, insomnia, and fatigue.1,4 Whereas 
some sleep problems are directly associated with the dis-
ease, others derive from recent or current anticancer thera-
pies. While or after undergoing cancer therapies, the most 
common symptoms cancer patients experience include 
excessive fatigue, leg restlessness, insomnia, and increased 
sleepiness.1 Suffering from sleep problems affects both phys-
ical and mental components of quality of life. The observed 
association between insomnia and sedative/hypnotic use4 
suggests that the standard medications are not effective 
enough. This and the fact that cancer patients often take 
several medications, some of which are associated with 
numerous and strong side-effects, makes the search for 
new, effective, and well-tolerated medications for sleeping 
problems worthwhile.
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Abstract
Hypothesis. Cancer patients frequently suffer from poor sleep quality. Bryophyllum pinnatum is a herbal medication used in 
anthroposophic medicine, which has been shown to be associated with improvements in sleep quality during pregnancy 
with only few and minor or moderate side-effects reported. In this study, the sleep quality of cancer patients during 
treatment with B pinnatum was investigated. Study Design. In this prospective, observational study, cancer patients suffering 
from sleep problems were treated with B pinnatum (350 mg tablets, corresponding to 50% of leaf pressed juice [Weleda 
AG, Arlesheim, Switzerland], dosage at physician’s consideration, but most frequently 2 tablets with evening meal and 2 
before going to bed). Methods. Sleep quality (Pittsburgh Sleep Quality Index [PSQI]), daily sleepiness (Epworth Sleeping 
Scale [ESS]), and fatigue (Fatigue Severity Scale [FSS]) were assessed at the beginning of the treatment and after 3 weeks. 
Possible adverse drug reactions perceived by the patients during the treatment were recorded. From the 28 recruited 
patients, 20 completed both questionnaires and were considered in the present analysis. Data are expressed as mean 
± standard deviation. Results. Patients were 61 ± 10.4 years old and the majority were female (17 out of 20). During 
treatment with B pinnatum, the PSQI decreased from 12.2 ± 3.62 to 9.1 ± 3.61 (P < .01), and ESS changed from 8.4 ± 3.18 
to 7.1 ± 3.98 (P < .05). There was no change in FSS. The treatment was well tolerated by the majority of patients, with 
only 6 patients reporting discomfort that might have been caused by B pinnatum (fatigue n = 3, dry throat n = 1, agitation 
n = 1, difficult digestion n = 1). No serious adverse drug reactions were detected. Conclusion. B pinnatum may be a suitable 
treatment for sleep problems of cancer patients. Controlled, randomized clinical trials of the use of B pinnatum in sleep 
disorders are urgently needed.
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Bryophyllum pinnatum (Lamarck) Oken [syn.: 
Kalanchoe pinnata (Lamarck) Persoon, syn.: Bryophyllum 
calycinum Salisbury] is a plant of the family Crassulaceae. 
It is originally from Madagascar but can now be found 
across tropical Africa, tropical America, India, China, and 
Australia.5 The plant is known under various common 
names, such as life plant, air plant, love plant, Cathedral 
bells, and Goethe plant. Leaf extracts from B pinnatum have 
been used in traditional medicine of the regions where it 
grows and are suggested to have the following properties: 
sedative, central nervous system depressant, anticancer, 
analgesic, antipyretic, muscle relaxant, gastroprotective, 
anti-inflammatory, antiseptic, anti-allergic, anti-anaphylac-
tic, immunomodulating, and wound healing.5-10 Until 
recently, evidence for the sedative effects was exclusively 
preclinical, with different fractions shown to potentiate pen-
tobarbitone-induced sleeping time in in vivo models, that is, 
to possess a depressant action on the central nervous sys-
tem.11,12 The anticancer potential of B pinnatum has been 
demonstrated by a study showing that crude leaf extracts 
inhibit in vitro growth of human cervical cancer cells and 
induce apoptosis.10 Its safety was recently supported by a 
study showing that at relatively high concentrations, both 
aqueous and ethanolic B pinnatum leaf extracts can inhibit 
N-diethylnitrosamine-induced hepatic injury in rats.13
In the 1920s, in Europe, B pinnatum started to be used in 
anthroposophic medicine as a treatment for “hysteria.”14 A 
half century later, B pinnatum was introduced in obstetrics 
at the anthroposophic Herdecke Community Hospital 
(Germany) for the treatment of premature labor.15 
Subsequently, several experimental and clinical studies cor-
roborated its tocolytic effects and revealed the correspond-
ing mechanism of action.16-21 More recently, B pinnatum 
was shown to have potential in the treatment of overactive 
bladder.22,23 A characterization of the B pinnatum prescrib-
ing pattern among a network of anthroposophic physicians 
revealed sleep disorders to be one of the most frequent diag-
noses for which it is prescribed.24 A first observational study 
on pregnant women confirmed that improvements in sleep 
quality can be observed during treatment with B pinna-
tum.25 This patient group was chosen because pregnant 
women have poorer sleep quality than nonpregnant 
women,26 while treatment with sedatives is particularly 
problematic during pregnancy due to possible undesirable 
effects for mother and embryo/fetus. Irrespective of the 
indication (preterm contractions,18 overactive bladder,23 and 
sleep problems during pregnancy25), all clinical studies doc-
umented a good tolerability of B pinnatum.
This favorable tolerability, the previous observational 
study on pregnant women, and the particular vulnerabilities 
of cancer patients prompted us to conduct the present obser-
vational, prospective study on the treatment of cancer-
related sleeping problems with B pinnatum. The suspected 
anticancer properties of B pinnatum preparations were not 
addressed in the present study; they are however reassuring 
inasmuch as a possible disadvantageous impact of the 
extracts on tumor progression can be ruled out.
Materials and Methods
Study Design
This prospective, observational study was authorized by the 
ethical committee of canton of Zurich as well as by the 
Swiss Agency for Therapeutic Products and was performed 
according to good clinical practice. Written informed con-
sent was obtained from all study participants. Patients of the 
Paracelsus-Hospital Richterswil were included in the study 
if (a) they were outpatients; (b) their age was between 18 
and 80 years; (c) they had an oncological disease; (d) their 
Eastern Cooperative Oncology Group (ECOG) index was 
0, 1, or 2 (ie, patients could be up more than 50% of waking 
hours); (e) they had been prescribed B pinnatum 50% 
(chewable tablets 350 mg, dosage depending on physician’s 
prescription) for at least 21 consecutive days for sleep dis-
orders or changes in sleep behavior perceived by the patients 
as being associated with the cancer disease; and (f) they had 
basic knowledge of German. Excluded from this study were 
cancer patients who did not fulfill the inclusion criteria or 
(a) had received treatment for their sleep problems before 
the onset of the cancer disease; (b) had an alcohol depen-
dence and/or consumed intoxicants; (c) or presented with 
acute impairment of consciousness, acute psychosis, or 
dementia; or (d) were under acute life-threatening condi-
tions. At the beginning of the study, an additional exclusion 
criterion was treatment with soporifics (affecting 11 
patients); after an authorized amendment to the study proto-
col, this criterion was replaced by a change in the dosage of 
medication likely to affect sleep quality, either during the 3 
weeks before the study started or during the study period.
By analogy with the previous observational study on 
pregnant women, the study had been designed to include 50 
patients.25 Due to the slow recruitment rate, however, the 
study was stopped when 40% of the patients had finished 
the study. An analysis of the main outcomes was performed 
and the data are presented here.
Study Medication
Participants were treated with B pinnatum (chewable tablets 
350 mg, 50% leaf pressed juice on lactose, corresponding to 
175 mg of fresh plant per tablet) based on a clinical indica-
tion. The dosage depended on the physician’s prescription 
(3-8 tablets per day). The tablets were manufactured by 
Weleda AG, Arlesheim, Switzerland, with B pinnatum 
plants provided by Weleda, Brazil, and are registered at the 
Swiss Agency for Therapeutic Products (without indica-
tion). A voucher specimen of B pinnatum plants provided 
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by Weleda, Brazil (No. ZSS 29717) has been deposited at 
the Zurich Succulent Plant Collection, Switzerland. 
Previous analytical work on the pressed juice of fresh or 
fresh frozen B pinnatum leaves, which are routinely used to 
manufacture B pinnatum chewable tablets, revealed the 
presence of flavonoid glycosides as major constituents, and 
several bufadienolides as minor components.27
Measurements
A detailed questionnaire was completed by the participants 
on day 1 (before treatment with B pinnatum) and on day 22 
(at the end of 21 days of treatment). At each occasion, it 
addressed the 2 previous weeks and contained the Pittsburgh 
Sleep Quality Index (PSQI) to assess sleep quality,28,29 the 
Epworth Sleeping Scale (ESS),30 and the Fatigue Severity 
Scale (FSS).31 In addition, patients were asked to specify 
possible discomforts that they believed to be caused by B 
pinnatum.
The PSQI index was developed as a self-rated question-
naire to characterize sleep quality, and the corresponding 
values can vary between 0 and 21, with higher values repre-
senting worse sleep quality, whereby a cutoff of >5 has con-
siderable diagnostic sensitivity (89.6%) and specificity 
(86.5%) in distinguishing good and poor sleepers.28 The 
PSQI index comprises the following components: “sleep 
quality” (Comp1), “sleep latency” (Comp2), “sleep dura-
tion” (Comp3), “habitual sleep efficiency” (Comp4), “sleep 
disturbance” (Comp5), “use of sleeping medication” 
(Comp6), and “daytime dysfunction” (Comp7).
Statistics
The statistical analysis was performed in SPSS for Windows, 
Version 19; differences between the scores before and at the 
end of treatment were compared with the t test for paired 
samples if the data had a normal distribution (ie, Z-score for 
both skewness and kurtosis ≤1.96), otherwise using the 
Wilcoxon signed rank test. Differences were considered to 
be statistically significant if P ≤ .05. Data are expressed as 
mean ± standard deviation (SD). For each question, the total 
number of answers (n) is shown, if different from 20.
Results
From February 2013 until March 2014, 28 patients were 
recruited, of whom 21 finished the study. The reasons for 
study dropout were the following: therapy stopped (n = 4; in 
2 cases due to lack of compliance; in the others, because 
curative therapies were seen as more important), therapy 
had been carried out but the questionnaires had not been 
completed (n = 2, due to lack of time and lost question-
naire), and unknown (n = 1). Of the 21 participants who 
finished the study, one was excluded because more than 
67% of the questions of the second questionnaire had not 
been answered. Hence, data from 20 patients could be eval-
uated. All 20 evaluated patients filled in the questionnaire at 
the beginning of the treatment and 3 weeks later.
The main demographic characteristics and disease char-
acteristics of these patients are depicted in Table 1. The 
mean patient age was 61 years. The majority lived with a 
partner, were of female gender, were postmenopausal, 
exhibited a normal body mass index, had additional dis-
eases (other than cancer), and were taking other medica-
tions. All patients complained of sleep disorders or changes 
in sleep behavior (one of the inclusion criteria), which were 
mostly long-lasting (2 years on average, median 1 year). 
The severity of their sleep problems translated into rela-
tively high PSQI values at study beginning (12 ± 3.6 in a 0 
to 21 scale; Figure 1; see Discussion) that in all but one case 
(5; ie, borderline) were above the cutoff value used to define 
poor sleepers (>5). Concerning the malignant disease, most 
patients were suffering from breast cancer, were in remis-
sion, and had a favorable ECOG performance status. The 
cancer disease had been diagnosed on average 5 ± 6.2 years 
previously (median 2 years). Most patients had undergone 
several cancer-related therapies in the past (more than 1 
month before the study); in the month prior to the study as 
well as during the study, mistletoe therapy was the most 
frequently mentioned therapy.
During treatment with B pinnatum, sleep quality of the 
participating cancer patients improved markedly, inasmuch 
as a statistically significant reduction of PSQI was observed 
(from 12.2 ± 3.62 down to 9.1 ± 3.61, P = .002; Figure 1). 
It should be kept in mind that the higher the values of the 
global PSQI (and of the corresponding components), the 
worse the sleep quality. The number of patients below the 
cutoff for poor sleepers (ie, PSQI >5) increased from 1 at 
study beginning (PSQI = 5) to 3 (PSQI values of 4, 3, and 
3). When the different PSQI components were compared at 
the beginning and at the end of the treatment (Figure 2), 
improvements of subjective sleep quality (1.7 ± 0.67 vs 1.1 
± 0.79, P = .008), sleep latency (2.6 ± 0.71 vs 2.1 ± 0.75, 
P = .024), habitual sleep efficiency (1.9 ± 1.02 vs 1.4 ± 
1.04, P = .045), sleep disturbance (1.7 ± 0.59 vs 1.4 ± 0.59, 
P = .014), and a reduction in the use of sleeping medication 
(1.3 ± 1.41 vs 0.45 ± 1.10, P = .035) were detected. A ten-
dency for an improvement was observed in the case of sleep 
duration (1.9 ± 1.09 vs 1.35 ± 1.19, P = .160). No signifi-
cant alteration was detected in daytime dysfunction (1.4 ± 
0.75 vs 1.5 ± 0.76, P = .739).
ESS analysis revealed a statistically significant decrease 
in mean daily sleepiness (Figure 3; P = .048). On the other 
hand, no alteration in fatigue could be observed during the 
study period (36.6 ± 11.75 at the treatment start vs 36.2 ± 
12.56 at the end of treatment, P = .802).
Although the treating physicians were free to decide on 
the medication dosage, in most cases (n = 17), the patients 
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had been instructed to take 2 B pinnatum tablets, twice daily 
(with the evening meal and when going to bed). A few dis-
comforts, all of minor severity, were reported by patients to 
be possibly caused by the study medication (see Table 1). 
They consisted of fatigue, dry throat, agitation, and difficult 
Table 1. Patient Characteristics and Reported Discomforts 
Possibly Caused by Bryophyllum pinnatuma.
N (or mean ± SD)
Age (years) 61 ± 10.4
Female patients 17
Household structure 14
 Lives alone 6
 Lives with partner 10
 Lives with partner and children 3
 Lives with a daughter 1
BMI (n = 17) 20 ± 4.8
Hormonal situation (women only)
 Premenopausal 2
 Perimenopausal 1
 Postmenopausal 14
 NK 3
Duration of sleep problems  
(n = 17, in years)
2 ± 2.1b
Cancer type
 Breast 12
 Prostate 2
 Colon 2
 Lung 1
 Uterus sarcoma 1
 Oral 1
 Hairy cell leukemia 1
Cancer disease activity
 Complete remission 10
 Partial remission 2
 Small change 3
 Progression 2
ECOG-Karnofsky index
 0 16
 1 4
Time since cancer diagnosis (years) 5 ± 6.2
Anticancer therapies (before last month)
 Surgery 14
 Chemotherapy 7
 Radiation therapy 3
 Hormonal therapy 7
 Mistletoe therapy 13
 Hyperthermia 5
Anticancer therapies (last month)
 Surgery 1
 Chemotherapy 3
 Radiation therapy 3
 Hormonal therapy 3
 Mistletoe therapy 11
 Hyperthermia 5
Anticancer therapies (during the study)
 Surgery 1
 Chemotherapy 3
 Radiation therapy 1
 Hormonal therapy 6
 Mistletoe therapy 16
(continued)
Table 1. (continued)
N (or mean ± SD)
 Hyperthermia 4
Additional diseases 13
 Hypertonia 6
 Psychological diseases 4
 Allergies 5
 Others 4
Current additional medications 15
 High blood pressure 
medications
6
 Cholesterol-lowering drugs 3
 Soporifics 3
 Analgesics 2
 Others 11
Discomforts possibly caused by  B 
pinnatum
6
 Fatigue 3
 Dry throat 1
 Agitation 1
 Difficult digestion 1
Abbreviations: NK, not known; BMI, body mass index; ECOG, Eastern 
Cooperative Oncology Group index.
aN = 20; except when indicated.
bOne patient answered “several weeks,” 2 patients wrote “several 
years”; for the calculations, “several” was replaced by “2”; median was 
1 year.
Figure 1. Improvement in sleep quality of cancer patients as 
assessed by the Pittsburgh Sleep Quality Index (PSGI; P = .002) 
during treatment with B pinnatum for 3 weeks.
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digestion. No severe adverse reactions were reported by any 
patient at any time. One patient in the perimenopausal 
period reported personally on her own initiative a clear-cut 
improvement in hot flashes.
Discussion
Some of the symptoms triggered by a cancer disease and 
initial treatment, for example, sleep disturbances and fatigue, 
are long-lasting, with cancer survivors experiencing them 
even more than 10 years thereafter.2 In the present study, 
patients had become aware of their cancer disease on aver-
age 5 years (median 2 years) before entering the study, and 
their sleep disturbances were mostly long-lasting (2 years on 
average, median 1 year) and strong. Indeed, the average 
baseline PSQI of 12 is relatively high in comparison with 
values from other studies (often 8-932-35 is reported among 
breast cancer patients, or 8 for elderly patients36), rather cor-
responding to the value initially found among depressive 
patients.28 In the present study, the majority of patients were 
not undergoing invasive anticancer therapies—surgery, che-
motherapy, and radiotherapy—during or in the month 
before the study, that is, the short-term effects of such thera-
pies were unlikely to be affecting day-to-day well-being or 
activity.
During treatment with B pinnatum, a statistically signifi-
cant (P = .002) improvement of sleep quality as assessed by 
the PSQI was observed. This averaged index decreased from 
12 to 9 during treatment, which is likely to be clinically rel-
evant, even though most patients did not attain values charac-
teristic of good sleepers at the end of the study. Whether a 
3-point improvement renders the sleep problems of cancer 
patients such as those of the present study bearable or whether 
additional treatments should be followed requires further 
investigation. However, a 3-point improvement compares 
well with differences of 1 to 1.5 points after 4 weeks of (elec-
tro)acupuncture for breast cancer patients34,37 and is only 
slightly inferior to the decrease in 4 points during acupunc-
ture that was observed among elderly patients.36 A previous 
study on the effect of mindfulness-based stress reduction on 
subjective and objective sleep parameters in women with 
Figure 2. Most components of the Pittsburgh Sleep Quality Index improved during treatment of cancer patients with B pinnatum for 
3 weeks.
Figure 3. Reduction of daily sleepiness (Epworth Sleeping 
Scale [ESS], P = .048) of cancer patients during treatment with B 
pinnatum for 3 weeks.
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breast cancer revealed only a tendency for a reduction of 
approximately 0.6 in PSQI, which was however inferior to 
the improvement detected by objective sleep parameters.33
In the present study, all PSQI components but one—day-
time dysfunction—were higher at study beginning than 
after 3 weeks of treatment, suggesting a manifold improve-
ment. The present observations corroborate the results 
obtained in the former prospective clinical study about the 
effect of B pinnatum on sleep quality during pregnancy.25 
Here, significant improvements in subjective sleep quality 
and a reduction in sleep disturbances were detected. Taken 
together, the 2 studies indicate that B pinnatum is effective 
for multiple types of sleep problems. The improvements in 
PSQI observed here are highly statistically significant even 
though the number of patients was smaller than initially 
planned and in comparison with the previous study (20 vs 
50). This suggests that the improvements were more clear-
cut than initially expected.
Cancer patients suffer not only from sleep problems at 
night but also from daily sleepiness and fatigue.1 The statisti-
cally significant ESS reduction toward a value similar to the 
average obtained with healthy subjects (6 ± 2.230) that was 
observed here suggests that B pinnatum might be helpful in 
this respect as well. Comparable results were obtained in a 
previous study with pregnant women.25 Also as in this previ-
ous study, no improvement in fatigue was detected with the 
FSS, an observation that is corroborated by the lack of change 
in the PSQI component daytime dysfunction. These results 
must be interpreted in view of the study population, which at 
treatment beginning exhibited initial FSS scores only slightly 
higher than those typical for healthy subjects, that is, up to 
36.31 Furthermore, the lack of change in average fatigue and 
daytime dysfunction suggests that the 3 cases of patients 
mentioning fatigue as a discomfort that might have been 
caused by B pinnatum should be interpreted with caution. 
Indeed, only in one of these cases were concomitant increases 
in FSS and in daytime dysfunction during the study period 
detected (data not shown). The discomforts mentioned might 
reflect patients’ own subjective perceptions (particularly 
comprehensible in the course of malignant diseases), which 
might be associated with the (expected) sedative and/or mus-
cle relaxing effect of the study medication.11,12
The main limitation of this study is the lack of a control 
group and patient randomization, which prevents the dem-
onstration of a causal relationship between intake of B pin-
natum and improvement of sleep quality. However, 
improvements were observed in most but not all measured 
parameters, suggesting that the patients were answering the 
questions truthfully and not merely trying to fulfill the 
researchers’ expectations. Since in most cases patients had 
been aware of their cancer disease for a considerable period 
and the sleep problems mentioned were long-lasting, one 
can assume that patients’ situation was relatively stable and 
spontaneous improvements were unlikely.
Herbal medications, such as those prepared from B pinna-
tum, are often multitarget medicines with a pleiotropic effect 
profile.38 Accordingly, B pinnatum preparations are frequently 
prescribed as a treatment for organic and nonorganic sleep dis-
orders, but also for several other diagnoses.24 To a certain 
extent, some of these—depressions, anxiety disorders, reac-
tions to severe stress, and adjustment disorders, symptoms, and 
signs involving emotional state as well as menopausal and 
other perimenopausal disorders—might have been pertinent to 
the outcomes of the present study. In other words, possible 
improvements in some of these (co)diagnoses might have con-
tributed to the observed improvements in sleep quality and 
daily sleepiness. Whereas this multitude of possible indica-
tions might shed some doubts on which might be the exact 
condition that was most improved during treatment with B 
pinnatum, it can be clinically advantageous. The example of 
the patient who took the initiative of reporting an improve-
ment in hot flashes illustrates this pragmatic perspective.
Conclusion
The present work shows that the sleep quality of cancer 
patients significantly improved under treatment with B pin-
natum and that this medication was well tolerated in this 
clinical context. The significant and additionally observed 
favorable effect of B pinnatum on daytime sleepiness may 
be associated with the improvement in sleep quality and 
turned out to be independent of fatigue, which did not 
change during the study. No serious adverse event occurred 
during treatment.
Authors’ Note
In addition to A. P. Simões-Wüst, PhD, K. Fürer, PhD, and U. von 
Mandach, PhD, the Bryophyllum Collaborative Group includes C. 
Betschart, MD, R. Brenneisen, PhD, M. Hamburger, PhD, M. 
Mennet, PhD, O. Potterat, PhD, and M. Schnelle, MD.
Acknowledgments
We express our gratitude to the participating patients and thank the 
outpatient clinic Paracelsus-Hospital Richterswil for the opportu-
nity to perform this study. We thank Claudia Lambrigger-Steiner, 
who contributed to the elaboration of the study documents and 
Heather Murray for language corrections. Weleda AG (Arlesheim, 
Switzerland) provided the Bryophyllum pinnatum tablet medica-
tion free of charge to the study participants. Financial support by 
the Johannes Kreyenbühl Foundation and by Weleda AG is grate-
fully acknowledged.
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest 
with respect to the research, authorship, and/or publication of this 
article: Ana Paula Simões-Wüst and Ursula von Mandach received 
over the last 5 years occasional research funds from the Weleda 
AG, the producer of Bryophyllum pinnatum preparations.
 at UZH Hauptbibliothek / Zentralbibliothek Zürich on December 23, 2015ict.sagepub.comDownloaded from 
458 Integrative Cancer Therapies 14(5) 
Funding
The author(s) disclosed receipt of the following financial support 
for the research, authorship, and/or publication of this article: 
Financial support by the Johannes Kreyenbühl Foundation and by 
Weleda AG.
References
 1. Parish JM. Sleep-related problems in common medical condi-
tions. Chest. 2009;135:563-572.
 2. Harrington CB, Hansen JA, Moskowitz M, Todd BL, 
Feuerstein M. It’s not over when it’s over: long-term 
symptoms in cancer survivors—a systematic review. Int J 
Psychiatry Med. 2010;40:163-181.
 3. Sateia MJ, Lang BJ. Sleep and cancer: recent developments. 
Curr Oncol Rep. 2008;10:309-318.
 4. Davidson JR, MacLean AW, Brundage MD, Schulze K. 
Sleep disturbance in cancer patients. Soc Sci Med. 2002;54: 
1309-1321.
 5. Kamboj A, Saluja A. Bryophyllum pinnatum (Lam.) Kurz.: 
phytochemical and pharmacological profile: a review. 
Pharmacognosy Rev. 2009;3:364-374.
 6. El Abdellaoui S, Destandau E, Toribio A, et al. Bioactive mol-
ecules in Kalanchoe pinnata leaves: extraction, purification, 
and identification. Anal Bioanal Chem. 2010;398:1329-1338.
 7. Nayak BS, Marshall JR, Isitor G. Wound healing potential 
of ethanolic extract of Kalanchoe pinnata Lam. Leaf—a pre-
liminary study. Indian J Exp Biol. 2010;48:572-576.
 8. Kamgang R, Mboumi RY, Fondjo AF, Tagne MA, N’Dille 
GP, Yonkeu JN. Antihyperglycaemic potential of the water-
ethanol extract of Kalanchoe crenata (Crassulaceae). J Nat 
Med. 2008;62:34-40.
 9. Ojewole JA. Antinociceptive, anti-inflammatory and antidia-
betic effects of Bryophyllum pinnatum (Crassulaceae) leaf 
aqueous extract. J Ethnopharmacol. 2005;99:13-19.
 10. Mahata S, Maru S, Shukla S, et al. Anticancer property of 
Bryophyllum pinnata (Lam.) Oken. leaf on human cervical 
cancer cells. BMC Complement Altern Med. 2012;12:15.
 11. Pal S, Sen T, Chaudhuri AK. Neuropsychopharmacological 
profile of the methanolic fraction of Bryophyllum pinnatum 
leaf extract. J Pharm Pharmacol. 1999;51:313-318.
 12. Yemitan OK, Salahdeen HM. Neurosedative and muscle 
relaxant activities of aqueous extract of Bryophyllum pinna-
tum. Fitoterapia. 2005;76:187-193.
 13. Afzal M, Kazmi I, Anwar F. Antineoplastic potential of 
Bryophyllum pinnatum Lam. on chemically induced hepato-
carcinogenesis in rats. Pharmacognosy Res. 2013;5:247-253.
 14. Daems W. Kurzgefsste Byophyllum-Chronologie. 
Korrespondenzblätter für Ärzte, Arlesheim. 1982;105.
 15. Hassauer W, Schreiber K, Von der Decken D. Ein neuer 
Weg in der tokolytischen Therapie. Erfahrungsheikunde. 
1985;34:683-687.
 16. Daub E. Vorzeitige Wehentätigkeit. Ihre Behandlung mit 
pflanzlichen Substanzen, eine klinische Studie. Stuttgart, 
Germany: Urachhaus; 1989.
 17. Vilaghy I. Decreasing the rate of premature delivery with 
phytotherapy—results from general practice. Ther Umsch. 
2002;59:696-701.
 18. Plangger N, Rist L, Zimmermann R, von Mandach U. 
Intravenous tocolysis with Bryophyllum pinnatum is better 
tolerated than beta-agonist application. Eur J Obstet Gynecol 
Reprod Biol. 2006;124:168-172.
 19. Gwehenberger B, Rist L, Huch R, von Mandach U. Effect of 
Bryophyllum pinnatum versus fenoterol on uterine contractil-
ity. Eur J Obstet Gynecol Reprod Biol. 2004;113:164-171.
 20. Wächter R, Brenneisen R, Hamburger M, et al. Leaf press 
juice from Bryophyllum pinnatum (Lamarck) Oken induces 
myometrial relaxation. Phytomedicine. 2011;19:74-82.
 21. Simões-Wüst AP, Grãos M, Duarte CB, et al. Juice of 
Bryophyllum pinnatum (Lam.) inhibits oxytocin-induced 
increase of the intracellular calcium concentration in human 
myometrial cells. Phytomedicine. 2010;17:980-986.
 22. Schuler V, Suter K, Fürer K, et al. Bryophyllum pinnatum 
inhibits detrusor contractility in porcine bladder strips—a 
pharmacological study towards a new treatment option of 
overactive bladder. Phytomedicine. 2012;19:947-951.
 23. Betschart C, von Mandach U, Seifert B, et al. Randomized, 
double-blind placebo-controlled trial with Bryophyllum pin-
natum versus placebo for the treatment of overactive blad-
der in postmenopausal women. Phytomedicine. 2012;20: 
351-358.
 24. Simões-Wüst AP, Jeschke E, Mennet M, Schnelle M, Matthes 
H, von Mandach U. Prescribing pattern of Bryophyllum 
preparations among a network of anthroposophic physicians. 
Forsch Komplementmed. 2012;19:293-301.
 25. Lambrigger-Steiner C, Simões-Wüst AP, Kuck A, Fürer K, 
Hamburger M, von Mandach U. Sleep quality in pregnancy 
during treatment with Bryophyllum pinnatum: an observa-
tional study. Phytomedicine. 2013;21:753-757.
 26. Brunner DP, Munch M, Biedermann K, Huch R, Huch A, 
Borbely AA. Changes in sleep and sleep electroencephalo-
gram during pregnancy. Sleep. 1994;17:576-582.
 27. Fürer K, Raith M, Brenneisen R, et al. Two new flavonol gly-
cosides and a metabolite profile of Bryophyllum pinnatum, a 
phytotherapeutic used in obstetrics and gynaecology. Planta 
Med. 2013;79:1565-1571.
 28. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer 
DJ. The Pittsburgh Sleep Quality Index: a new instru-
ment for psychiatric practice and research. Psychiatry Res. 
1989;28:193-213.
 29. Monk TH, Reynolds CF, Kupfer DJ, et al. The Pittsburgh 
Sleep Diary. J Sleep Res. 1994;3:111-120.
 30. Johns MW. A new method for measuring daytime sleepiness: 
the Epworth Sleepiness Scale. Sleep. 1991;14:540-545.
 31. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The 
fatigue severity scale. Application to patients with multiple 
sclerosis and systemic lupus erythematosus. Arch Neurol. 
1989;46:1121-1123.
 32. Khoramirad A, Mousavi M, Dadkhahtehrani T, Pourmarzi D. 
Relationship between sleep quality and spiritual well-being/
religious activities in Muslim women with breast cancer [pub-
lished online December 9, 2014]. J Relig Health. doi:10.1007/
s10943-014-9978-0.
 33. Lengacher CA, Reich RR, Paterson CL, et al. The effects 
of mindfulness-based stress reduction on objective and sub-
jective sleep parameters in women with breast cancer: a 
 at UZH Hauptbibliothek / Zentralbibliothek Zürich on December 23, 2015ict.sagepub.comDownloaded from 
Simões-Wüst et al 459
randomized controlled trial [published online June 18, 2014]. 
Psycho-oncology. doi:10.1002/pon.3603.
 34. Bao T, Cai L, Snyder C, et al. Patient-reported outcomes in 
women with breast cancer enrolled in a dual-center, double-
blind, randomized controlled trial assessing the effect of 
acupuncture in reducing aromatase inhibitor-induced muscu-
loskeletal symptoms. Cancer. 2014;120:381-389.
 35. Ancoli-Israel S, Liu L, Rissling M, et al. Sleep, fatigue, 
depression, and circadian activity rhythms in women with 
breast cancer before and after treatment: a 1-year longitudinal 
study. Support Care Cancer. 2014;22:2535-2545.
 36. Zuppa C, Prado CH, Wieck A, Zaparte A, Barbosa A, Bauer 
ME. Acupuncture for sleep quality, BDNF levels and immu-
nosenescence: a randomized controlled study. Neurosci Lett. 
2014;587C:35-40.
 37. Mao JJ, Farrar JT, Bruner D, et al. Electroacupuncture for 
fatigue, sleep, and psychological distress in breast cancer 
patients with aromatase inhibitor-related arthralgia: a ran-
domized trial. Cancer. 2014;120:3744-3751.
 38. Schwabl H, Vennos C, Saller R. Tibetan formulas as pleiotro-
pic signatures—application of network medicines in multimor-
bidity. Forsch Komplementmed. 2013;20 (suppl 2):35-40.
 at UZH Hauptbibliothek / Zentralbibliothek Zürich on December 23, 2015ict.sagepub.comDownloaded from 
